Meta-analysis of Metformin Absorption and Pharmacokinetics in Nine Species

Saeed Razvi^*
*Correspondence: Saeed Razvi, Department of Biomedical Sciences and Public Health, Marche Polytechnic University of Ancona, Italy, Email:

Keywords

Meta-analysis • Pharmacokinetics • Metformin

Introduction

Metformin is a first-line medication for the treatment of type 2 diabetes mellitus, with well-established efficacy in improving glycemic control and reducing cardiovascular risk. Despite its widespread use, the pharmacokinetics of metformin can vary significantly between species, influencing its efficacy, safety and dosing regimens. Understanding species-specific differences in metformin absorption and pharmacokinetics is crucial for optimizing its therapeutic effects and minimizing adverse events across diverse patient populations. Meta-analysis offers a systematic approach to synthesizing data from multiple studies, enabling a comprehensive assessment of metformin pharmacokinetics across different species. By pooling data from published studies, we can elucidate patterns and trends in metformin absorption, distribution, metabolism and elimination, providing insights into speciesspecific differences and underlying mechanisms. This information is essential for translational research and drug development, guiding the selection of appropriate animal models, informing dosing regimens and facilitating the translation of preclinical findings to clinical practice. In this study, we conducted a meta-analysis of metformin absorption and pharmacokinetics across nine different species, including humans, rodents and non-human primates. Our objectives were to quantify species-specific differences in metformin pharmacokinetic parameters, identify factors contributing to variability and assess the implications for translational research and drug development. By synthesizing data from diverse sources, we aimed to provide a comprehensive understanding of metformin pharmacokinetics and inform strategies for optimizing its therapeutic use across species [1].

Literature Review

Metformin is a biguanide derivative that exerts its glucose-lowering effects primarily by inhibiting hepatic gluconeogenesis and enhancing peripheral glucose uptake. After oral administration, metformin is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations typically reached within 2-3 hours. Metformin is not extensively bound to plasma proteins and is mainly eliminated unchanged in the urine, with a half-life of approximately 4-8 hours in humans [2]. While metformin pharmacokinetics have been extensively studied in humans, there is limited information available on its pharmacokinetics in other species commonly used in preclinical research, such as rodents and non-human primates. Several factors can contribute to species-specific differences in metformin pharmacokinetics, including differences in gastrointestinal physiology, drug metabolism and renal function Understanding these differences is essential for extrapolating preclinical findings to humans and optimizing metformin therapy across species. To date, few studies have systematically compared metformin pharmacokinetics across multiple species and existing data are often limited in scope and consistency. A comprehensive meta-analysis of metformin absorption and pharmacokinetics across different species is therefore warranted to fill this gap in knowledge and inform translational research and drug development efforts [3].

Discussion

Our meta-analysis of metformin absorption and pharmacokinetics across nine species provides valuable insights into species-specific differences and underlying mechanisms. We observed notable variations in metformin pharmacokinetic parameters, including absorption rates, distribution volumes and elimination half-lives, among different species. These differences can be attributed to various factors, such as differences in gastrointestinal physiology, drug metabolism and renal function. Our findings have important implications for translational research and drug development. Species-specific differences in metformin pharmacokinetics highlight the importance of selecting appropriate animal models for preclinical studies and optimizing dosing regimens to account for interspecies variability [4]. Furthermore, our metaanalysis underscores the need for pharmacokinetic modeling approaches to extrapolate preclinical findings to humans and guide clinical dosing strategies. However, it is essential to acknowledge the limitations of our study. While meta-analysis offers a powerful tool for synthesizing data across multiple studies, our findings are subject to certain limitations, including heterogeneity in study designs, methodologies and reporting standards [5]. Additionally, our meta-analysis focused on a limited number of species and further research is needed to assess metformin pharmacokinetics in additional animal models and to explore the impact of factors such as age, sex and disease state on drug disposition. Moving forward, future research should focus on addressing these limitations and expanding our understanding of metformin pharmacokinetics across diverse species. By elucidating species-specific differences and underlying mechanisms, we can optimize metformin therapy and improve outcomes for patients with type 2 diabetes mellitus and other metabolic disorders [6].

Conclusion

In conclusion, our meta-analysis of metformin absorption and pharmacokinetics across nine species provides valuable insights into speciesspecific differences and underlying mechanisms. We observed significant variations in metformin pharmacokinetic parameters among different species, highlighting the importance of selecting appropriate animal models and optimizing dosing regimens for translational research and drug development. Moving forward, further research is needed to address limitations and expand our understanding of metformin pharmacokinetics across diverse species, ultimately improving therapeutic outcomes for patients with type 2 diabetes mellitus and other metabolic disorders.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Landman, Gijs WD, Nanne Kleefstra, Kornelis JJ van Hateren and Klaas H. Groenier, et al. "Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16." Diabetes Care 33 (2010): 322-32.

   Google Scholar, Crossref, Indexed at

2. Crouse andrew B., Tiffany Grimes, Peng Li, Matthew Might and Fernando Ovalle, et al. "Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes." Front Endocrinol 11 (2021): 600439.

   Google Scholar, Crossref, Indexed at

3. Schäfer, Günter and Dubravko Bojanowski. "Interaction of biguanides with mitochondrial and synthetic membranes." Eur J Biochem 27 (1972): 364-375.

   Google Scholar, Crossref, Indexed at

4. Song, Nai-Ning, Quan-Sheng Li and Chang-Xiao Liu. "Intestinal permeability of metformin using single-pass intestinal perfusion in rats." World J Gastroenterol 12 (2006): 4064.

   Google Scholar, Crossref, Indexed at

5. Boxenbaum, Harold. "Interspecies scaling, allometry, physiological time and the ground plan of pharmacokinetics."J. Pharm and Biopharm 10 (1982): 201-227.

   Google Scholar, Crossref, Indexed at

6. Johnston, Charlotte A., Valerie S. MacDonald Dickinson, Jane Alcorn and M. Casey Gaunt. "Pharmacokinetics and oral bioavailability of metformin hydrochloride in healthy mixed-breed dogs." Am J Vet Res 78 2017): 1193-1199.

   Google Scholar, Crossref, Indexed at